Skip to main content
SpringerLink
Log in

Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis

  • Chapter
  • First Online:
Biologic and Systemic Agents in Dermatology

Abstract

The etiology of psoriasis is unknown, although it is generally believed to be a complex T cell-mediated inflammatory disease with a genetic basis [1, 2]. CD4+ T helper cells, called T helper (Th) 17 cells, are important in the pathogenesis of psoriasis [2–5]. Interleukin (IL)-23 stimulates survival and proliferation of Th17 cells and thus serves as a key upstream cytokine regulator for this disease. Within psoriatic skin lesions, IL-23 is overproduced by activated dermal dendritic cells, and this in turn stimulates Th17 cells within the skin to survive and produce cytokines, including IL-17A. IL-17A and other pro-inflammatory cytokines drive keratinocyte activation and hyperproliferation in psoriasis. This review will focus on the role of IL-23 in psoriasis pathogenesis and the therapeutic targeting of IL-23 by monoclonal antibodies in patients with psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

    Article  CAS  PubMed  Google Scholar 

  2. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–50.

    Article  PubMed  Google Scholar 

  3. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-b1. Expert Rev Dermatol. 2007;2(1):1–10.

    Article  Google Scholar 

  4. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008;128(5):1064–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–25.

    Article  CAS  PubMed  Google Scholar 

  7. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19(3):281–6.

    Article  CAS  PubMed  Google Scholar 

  8. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87–113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med. 2008;205(6):1447–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908–15.

    Article  CAS  PubMed  Google Scholar 

  11. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8(6):639–46.

    Article  CAS  PubMed  Google Scholar 

  12. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007;8(6):630–8.

    Article  CAS  PubMed  Google Scholar 

  13. Kagami S, Rizzo HL, Kurtz SE, Miller LS, Blauvelt A. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol. 2010;185(9):5453–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem. 2001;276(40):37692–9.

    Article  CAS  PubMed  Google Scholar 

  15. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol. 2006;177(11):7980–9.

    Article  CAS  PubMed  Google Scholar 

  16. Wiekowski MT, Leach MW, Evans EW, Sullivan L, Chen SC, Vassileva G, et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol. 2001;166(12):7563–70.

    Article  CAS  PubMed  Google Scholar 

  17. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS, Stingl G. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol. 2003;170(11):5438–44.

    Article  CAS  PubMed  Google Scholar 

  18. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–51.

    Article  CAS  PubMed  Google Scholar 

  20. Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186(3):1495–502.

    Article  CAS  PubMed  Google Scholar 

  21. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005;102(6):2075–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006;177(7):4917–26.

    Article  CAS  PubMed  Google Scholar 

  23. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950–7.

    Article  CAS  PubMed  Google Scholar 

  25. Lillis JV, Guo CS, Lee JJ, Blauvelt A. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol. 2010;146(8):918–9.

    Article  PubMed  Google Scholar 

  26. Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MB. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers—IL-12, IL-18 and IL-23. Exp Dermatol. 2004;13(12):764–72.

    Article  CAS  PubMed  Google Scholar 

  27. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175(4):2721–9.

    Article  CAS  PubMed  Google Scholar 

  28. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A. 2005;102(52):19057–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H, et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002;30(2):161–6.

    Article  CAS  PubMed  Google Scholar 

  30. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–90.

    Article  CAS  PubMed  Google Scholar 

  31. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122:201–6.

    Article  CAS  PubMed  Google Scholar 

  32. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128(7):1653–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011;6(2):e17160.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol. 2006;176(7):4431–9.

    Article  CAS  PubMed  Google Scholar 

  37. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol. 2000;164(12):6621–32.

    Article  CAS  PubMed  Google Scholar 

  38. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez Farinas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–83.

    Article  CAS  PubMed  Google Scholar 

  41. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123(6):1037–44.

    Article  CAS  PubMed  Google Scholar 

  42. Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23(5):1081–92.

    Article  CAS  PubMed  Google Scholar 

  43. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–92.

    Article  CAS  PubMed  Google Scholar 

  44. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74.

    Article  CAS  PubMed  Google Scholar 

  45. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84.

    Article  CAS  PubMed  Google Scholar 

  46. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–28.

    Article  CAS  PubMed  Google Scholar 

  47. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–45.

    Article  CAS  PubMed  Google Scholar 

  48. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–9.

    Article  CAS  PubMed  Google Scholar 

  49. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. de Souza A, Ali-Shaw T, Reddy SM, Fiorentino D, Strober BE. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. Br J Dermatol. 2013;168(1):210–2.

    Article  PubMed  Google Scholar 

  52. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache OC. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010;162(5):1144–6.

    Article  CAS  PubMed  Google Scholar 

  53. Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38(11):1096–9.

    Article  CAS  PubMed  Google Scholar 

  54. Castineiras I, Fernandez-Diaz L, Juarez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39(8):730–1.

    Article  PubMed  Google Scholar 

  55. Buggiani G, D’Erme AM, Krysenka A, Pescitelli L, Lotti T, Prignano F. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. Dermatol Ther. 2012;25(3):283–5.

    Article  PubMed  Google Scholar 

  56. Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163(5):1116–8.

    Article  CAS  PubMed  Google Scholar 

  57. Bulai Livideanu C, Lahfa M, Mazereeuw-Hautier J, Paul C. Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology. 2010;221(4):321–3.

    Article  CAS  PubMed  Google Scholar 

  58. Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatol Treatment. 2013;24(3):179–87.

    Article  CAS  Google Scholar 

  59. Morales-Munera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol. 2013;168(4):820–4.

    Article  CAS  PubMed  Google Scholar 

  60. Chu DH, Van Voorhees AS, Rosenbach M. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases. Arch Dermatol. 2011;147(10):1228–30.

    Article  PubMed  Google Scholar 

  61. Puig L, Morales-Munera CE, Lopez-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology. 2012;225(1):14–7.

    Article  PubMed  Google Scholar 

  62. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66(5):731–41.

    Article  CAS  PubMed  Google Scholar 

  63. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–51.

    Article  CAS  PubMed  Google Scholar 

  64. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54.

    Article  CAS  PubMed  Google Scholar 

  65. Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11(10):1210–7.

    CAS  PubMed  Google Scholar 

  66. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280(5368):1435–8.

    Article  PubMed  Google Scholar 

  67. Altare F, Lammas D, Revy P, Jouanguy E, Doffinger R, Lamhamedi S, et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and salmonella enteritidis disseminated infection. J Clin Invest. 1998;102(12):2035–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Altare F, Jouanguy E, Lamhamedi S, Doffinger R, Fischer A, Casanova JL. Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol. 1998;10(4):413–7.

    Article  CAS  PubMed  Google Scholar 

  69. Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145–52.

    Article  CAS  PubMed  Google Scholar 

  70. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–71.

    Article  CAS  PubMed  Google Scholar 

  71. Tzellos T, Kyrgidis A, Trigoni A, Zouboulis CC. Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermato-Endocrinology. 2012;4(3):320–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol. 2013;68(5):863–5.

    Article  CAS  PubMed  Google Scholar 

  73. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862–72.

    Article  CAS  PubMed  Google Scholar 

  74. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300–12.

    CAS  PubMed  Google Scholar 

  75. Zuang Y, Calderon C, Marciniak SJ, Bouman-Thio E, Szapary P, Yang TW, et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016;72:1303–10.

    Article  Google Scholar 

  76. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133:1032–40.

    Article  CAS  PubMed  Google Scholar 

  77. Gordon KB, Callis Duffin K, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373:136–44.

    Article  CAS  PubMed  Google Scholar 

  78. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.

    Article  CAS  PubMed  Google Scholar 

  79. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.

    Article  CAS  PubMed  Google Scholar 

  80. Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521:222–6.

    Article  CAS  PubMed  Google Scholar 

  81. Papp K, Thaci D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-interleukin-23 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173:930–9.

    Article  CAS  PubMed  Google Scholar 

  82. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab, a selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: results from two randomised, controlled, phase 3 trials (reSURFACE 1 and reSURFACE 2). Lancet. 2017;390:276–8.

    Google Scholar 

  83. Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136:116–24.

    Article  CAS  PubMed  Google Scholar 

  84. Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger J, Lacour JP, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oregon Medical Research Center, 9495 SW Locust Street, Suite G, Portland, OR, 97223, USA

    Andrew Blauvelt MD, MBA

Authors
  1. Andrew Blauvelt MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Blauvelt MD, MBA .

Editor information

Editors and Affiliations

  1. Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, California, USA

    Paul S. Yamauchi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Blauvelt, A. (2018). Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66884-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66883-3

  • Online ISBN: 978-3-319-66884-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation